IPO uniQure (QURE) has developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Their first product, Glybera, was approved by the European Commission in October 2012 for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD. UniQure expects to launch Glybera commercially in selected European countries in the first half of 2014 through their collaboration with Chiesi Farmaceutici S.p.A.
Get an advisory report for this company's Initial Public Offering
View this company's prospectus
No comments:
Post a Comment